Pidotimod CAS#: 121808-62-6; 凯望编码 (ChemWhat Code): 87409
Identification
| 英文名 | Pidotimod |
| IUPAC Name | (4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid |
| 分子结构 |  |
| CAS编号 | 121808-62-6 |
| MDL Number | MFCD00867583 |
| 别名 | Pidotimod 121808-62-6 Pidotomod (R)-3-((S)-5-Oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid Pidotimod [INN] PGT/1A Pilimod NSC-759841 (R)-3-((S)-5-Oxoprolyl)-4-thiazolidinecarboxylic acid DTXSID0046199 Pidotimod (INN) (4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid (4R)-3-{[(2S)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic acid NCGC00160516-01 Polimod 785363R681 Pidotimodum Pigitil Pidotimodum [INN-Latin] 4-Thiazolidinecarboxylic acid, 3-[[(2S)-5-oxo-2-pyrrolidinyl]carbonyl]-, (4R)- SMR000466390 CCRIS 7271 BRN 6636310 Onaka Thymodolic acid Axil Timodolic acid Pilimod (TN) Pidotimod – Bio-X UNII-785363R681 PIDOTIMOD [MI] PIDOTIMOD [MART.] (R-(R,S))-3-((5-Oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylic acid PIDOTIMOD [WHO-DD] (4R)-3-[[(2S)-5-OXO-2-PYRROLIDINYL]CARBONYL]-4-THIAZOLIDINECARBOXYLIC ACID (R)-3-((S)-(5-Oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure [German] MLS000759528 MLS001032108 MLS001216453 MLS001423953 SCHEMBL138407 CHEMBL1488165 DTXCID8026199 Pidotimod, >=98% (HPLC) CHEBI:94618 HMS2051C04 HMS2231M03 HMS3715H06 Pharmakon1600-01502322 BCP05222 HY-B0944 Tox21_111865 MFCD00867583 NSC759841 s3106 (R)-3-((S)-(5-Oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure AKOS015896354 AC-3493 AM90280 CCG-100832 DB11364 KS-5229 NC00082 NSC 759841 (R)-3-[[(S)-5-Oxo-2-pyrrolidinyl]carbonyl]-1,3-thiazolidine-4-carboxylic Acid 4-Thiazolidinecarboxylic acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (R-(R,S))- NCGC00160516-03 BP164260 CAS-121808-62-6 NS00069185 P2147 SW197462-2 D07261 AB00639966-08 AB00639966_10 AB00639966_11 A804790 J-502193 Q3902720 (4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]thiazolidine-4-carboxylic acid;Pidotimod (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid (4R)-3-{[(2S)-5-OXOTETRAHYDRO-1H-PYRROL-2-YL]CARBONYL}-1,3-THIAZOLANE-4-CARBOXYLIC ACID |
| 分子式 | C9H12N2O4S |
| 分子量 | 244.27 |
| InChI | InChI=1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1 |
| InChI Key | UUTKICFRNVKFRG-WDSKDSINSA-N |
| Canonical SMILES | C1CC(=O)N[C@@H]1C(=O)N2CSC[C@H]2C(=O)O |
| Patent Information | ||
| Patent ID | Title | Publication Date |
| EP276752 | Derivative of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it | 1988 |
| EP450352 | Liposome formulations of immunomodulating drugs for the topical and aerosol administrations | 1991 |
| EP572942 | Oral pharmaceutical compositions for specific colon delivery | 1993 |
| US5369131 | Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam | 1994 |
Physical Data
| Appearance | White crystalline powder,odorless |
| Melting Point, °C | Solvent (Melting Point) |
| 195 – 197 | |
| 193.99 | |
| 194 – 198 | |
| 195 – 198 | propan-2-ol, H2O |
| Density, g·cm-3 | Measurement Temperature, °C |
| 1.509 | 19.84 |
Spectra
| Description (NMR Spectroscopy) | Nucleus (NMR Spectroscopy) | Solvents (NMR Spectroscopy) | Temperature (NMR Spectroscopy), °C |
| Chemical shifts, Spectrum | 1H | dimethylsulfoxide-d6 | |
| Chemical shifts, Spectrum | 13C | ||
| Spectrum | 1H | ||
| Chemical shifts, Spectrum | 1H | dimethylsulfoxide-d6 | |
| Chemical shifts, Spectrum | 13C | dimethylsulfoxide-d6 | |
| Spectrum | 1H | dimethylsulfoxide-d6 | 31.9 – 76.9 |
| Description (IR Spectroscopy) | Solvent (IR Spectroscopy) |
| Bands | potassium bromide |
| Bands, Spectrum | |
| Spectrum | KBr |
| Bands | KBr |
Route of Synthesis (ROS)
| Conditions | Yield |
| In ethanol; water at 5℃; for 5h; Solvent; Temperature; Sonication; Experimental Procedure Take 0.50g of pidotimod and 40ml of absolute ethanol to form a suspension by sonication. After dissolving the other 0.31g of histidine and 4ml of purified water, slowly add the histidine solution to the aforementioned pidotimod mixture at room temperature. Suspended solution, shake well after adding, cool to 5, continue to stir and crystallize for 5h,Filter to obtain crystalline powder, rinse with absolute ethanol 2 to 3 times,5ml each time, dried under vacuum at 40°C for 10 hours to constant weight to obtain pidotimod histidine salt, crystalline powder, yield 95.2%, purity 99.97% (active ingredient pidotimod detection) | 95.2% |
Safety and Hazards
No data available
Other Data
| Transportation | Under room temperature away from light |
| HS Code | |
| Storage | Under room temperature away from light |
| Shelf Life | 1 year |
| Market Price |
| Druglikeness | |
| Lipinski rules component | |
| 分子量 | 244.271 |
| logP | -1.007 |
| HBA | 6 |
| HBD | 2 |
| Matching Lipinski Rules | 4 |
| Veber rules component | |
| Polar Surface Area (PSA) | 112.01 |
| Rotatable Bond (RotB) | 3 |
| Matching Veber Rules | 2 |
| Quantitative Results | ||
| 1 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Derivative of thiazolidine-4-carboxylic acid, its preparation and pharmaceutical compositions containing it | |
| 2 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Toxicological evaluation of pidotimod | |
| 3 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | 3-L-(5-thioxo-L-prolyl)thiazolidine-4-carboxylic acid and derivatives therefrom, processes for the preparation thereof and pharmaceutical compositions containing them | |
| 4 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Pidotimod: The state of art | |
| 5 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Effects of pidotimod soluble powder and immune enhancement of Newcastle disease vaccine in chickens | |
| 6 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Antimicrobial and immunomodulatory properties and applications of marine-derived proteins and peptides | |
| 7 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Effects of Pidotimod on recurrent respiratory infections in children with down syndrome: A retrospective Italian study | |
| 8 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Laser therapy in cutaneous and genital warts: A review article | |
| 9 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Pidotimod injection with modified stability, and preparation method thereof | |
| 10 of 61 | Comment (Pharmacological Data) | Bioactivities present |
| Reference | Amantadine pidotimod carboxylate and preparation method and application thereof |
| Use Pattern |
| Pidotimod CAS#: 121808-62-6 is an immunomodulator suitable for patients with compromised immune function. It can be used for the prevention of acute infections, shorten the duration, and reduce the severity of the disease. It can be used as an adjunctive therapy during the acute infection period. |
试剂采购 | |
| 没有试剂厂商? | 向凯望发送快速询价 |
| 想要被列为试剂厂商? (付费服务) | 点击这里联系凯望 |
认证生产商 | |
| 想要被列为认证生产商 (需要通过认证)? | 请下载并填写 这份表格并发邮件到approved-manufacturers@chemwhat.com |
其他供应商 | |
| Watson International Limited | 访问Watson官网 |
如需其他帮助，请联系我们 | |
| 联系我们获取其它信息或服务 | 点击这里联系凯望 |